SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-032784
Filing Date
2021-06-14
Accepted
2021-06-14 16:21:16
Documents
68
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tals-10q_20210331.htm   iXBRL 10-Q 2411620
2 EX-31.1 tals-ex311_9.htm EX-31.1 20757
3 EX-31.2 tals-ex312_8.htm EX-31.2 20782
4 EX-32.1 tals-ex321_6.htm EX-32.1 9595
5 EX-32.2 tals-ex322_7.htm EX-32.2 9733
  Complete submission text file 0001564590-21-032784.txt   7984123

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA tals-20210331.xsd EX-101.SCH 45276
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tals-20210331_cal.xml EX-101.CAL 38565
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tals-20210331_def.xml EX-101.DEF 173038
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE tals-20210331_lab.xml EX-101.LAB 381464
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tals-20210331_pre.xml EX-101.PRE 305910
11 EXTRACTED XBRL INSTANCE DOCUMENT tals-10q_20210331_htm.xml XML 1424966
Mailing Address 201 E. JEFFERSON ST., SUITE 110B LOUISVILLE KY 40202
Business Address 201 E. JEFFERSON ST., SUITE 110B LOUISVILLE KY 40202 502-569-1059
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40384 | Film No.: 211014844
SIC: 2836 Biological Products, (No Diagnostic Substances)